Oncologianova
Welcome,         Profile    Billing    Logout  
 6 Trials 
14 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Emde, Till-Oliver
SASCIA, NCT04595565 / 2019-004100-35: Sacituzumab Govitecan in Primary HER2-negative Breast Cancer

Active, not recruiting
3
1332
Europe
Capecitabine, Xeloda, Carboplatin, Paraplatin, Cisplatin, Platinol, Sacituzumab govitecan, Trodelvy
German Breast Group, Gilead Sciences, Austrian Breast & Colorectal Cancer Study Group, Spanish Breast Cancer Research Group (GEICAM), ETOP IBCSG Partners Foundation, Cancer Trials Ireland, UNICANCER
HER2-negative Breast Cancer, Triple Negative Breast Cancer
03/27
03/29
ADAPTcycle, NCT04055493: Adj. Marker-adjusted Personalized Therapy Comparing ET+Ribociclib vs Chemotherapy in Intermediate Risk, HR+/HER2- EBC

Active, not recruiting
3
1684
Europe
Ribociclib 200Mg Oral Tablet, Kisqali
West German Study Group, Novartis, Genomic Health®, Inc.
Breast Cancer Female
07/27
07/27
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Recruiting
3
6000
Europe, Canada, Japan, US, RoW
Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane
Eli Lilly and Company
Breast Neoplasms
10/27
03/32
INFINITY, NCT04389541: Clinical Research Platform on Decision Making and Clinical Impact of Biomarker-Driven Precision Oncology

Completed
N/A
499
Europe
iOMEDICO AG, Bristol-Myers Squibb, Roche Pharma AG
Advanced Solid Tumors or Hematologic Malignancies
06/23
06/23
DigiNet, NCT05818449: Improvement of Personalized Lung Cancer Care Through Digital Connection and Patient Participation

Active, not recruiting
N/A
850
Europe
DigiNet intervention
University of Cologne, Gemeinsamer Bundesausschuss (G-BA), AOK Rheinland/Hamburg, AOK Nordwest, BARMER, University Hospital, Essen, Charite University, Berlin, Germany, Berlin Institute of Health, Helios Klinikum Emil von Behring, University Hospital Carl Gustav Carus, Deutsche Krebsgesellschaft e.V., Berufsverband der Niedergelassenen Hämatologen und Onkologen in Deutschland e.V., AOK Bundesverband, FOM Hochschule für Oekonomie und Management, University Medicine Greifswald, Technische Universität Dresden
Non-small Cell Lung Cancer Stage IV
03/25
03/25
REALTRK, NCT04557813: Registry for Molecular Testing, Treatment and Outcome of Patients With Solid Tumors Harboring a NTRK Gene Fusion

Active, not recruiting
N/A
88
Europe
iOMEDICO AG, Roche Pharma AG
NTRK Family Gene Mutation
10/26
10/26
Paula, Larissa de
EMBER-3, NCT04975308 / 2021-000079-35: A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer

Active, not recruiting
3
866
Europe, Japan, US, RoW
Imlunestrant, LY3484356, Exemestane, Fulvestrant, Abemaciclib, LY2835219
Eli Lilly and Company, Eli Lilly and Company
Breast Neoplasms, Neoplasm Metastasis
06/24
08/27
LIBRETTO-432, NCT04819100 / 2020-005191-35: A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)

Recruiting
3
170
Europe, Canada, Japan, US, RoW
Selpercatinib, LY3527723, LOXO-292, Placebo
Loxo Oncology, Inc., Eli Lilly and Company
Carcinoma, Non-Small-Cell Lung
05/27
08/32
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Recruiting
3
6000
Europe, Canada, Japan, US, RoW
Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane
Eli Lilly and Company
Breast Neoplasms
10/27
03/32
TACX Care, NCT04833998: Hydration Based on Thoitaine, Aloe Vera and Calendula, in the Prevention of Hand-Foot Syndrome in Patients Using Capecitabine

Recruiting
2
54
RoW
Extremecare, Placebo
Instituto Brasileiro de Controle do Cancer, Wecare Comércio de Cosméticos
Hand-foot Syndrome
11/21
12/21
NCT06062420: A Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck- GALAXIES H&N-202

Recruiting
2
360
Europe, Canada, Japan, US, RoW
Dostarlimab, Belrestotug, Nelistotug, GSK4381562
GlaxoSmithKline, iTeos Therapeutics
Neoplasms, Head and Neck
05/27
05/27
Exman, Pedro
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Recruiting
3
6000
Europe, Canada, Japan, US, RoW
Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane
Eli Lilly and Company
Breast Neoplasms
10/27
03/32
SCHOLAR-2, NCT04680442: Safety of Continuing HER-2 Directed Therapy in Overt Left Ventricular Dysfunction

Recruiting
2
130
Canada, RoW
Trastuzumab, Herceptin, Herzuma, Ogivri, Trazimera, Kanjinti, Pertuzumab, Perjeta, Trastuzumab emtansine, Kadcyla,
Population Health Research Institute
Breast Cancer, Heart Failure
01/25
06/25
Lerner, Lilian
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Recruiting
3
6000
Europe, Canada, Japan, US, RoW
Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane
Eli Lilly and Company
Breast Neoplasms
10/27
03/32

Download Options